Public Health Emergency of International Concern

Bolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster

Retrieved on: 
Wednesday, April 13, 2022
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, Medical Devices, Infectious Diseases, Other Health, Lazarus, Public Health Emergency of International Concern, CEO, The Warehouse Group, Gaps, Warehouse, Culture, COVID-19, NZD, Twitter, Software, Public health emergency, Research, NP, Leadership, Morrison, Deen Dayal Mobile Health Clinic, World, Infection, Patient, Growth, Vaccination, Vaccine, H. R. L. Morrison & Co, SP, Mobility, Antibody, Partnership, World Health Organization, Severe acute respiratory syndrome coronavirus 2, Accreditation, University, Pharmaceutical industry, Renewable energy, MD, Pictor

It will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Key Points: 
  • It will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).
  • The PictArray SARS-CoV-2 Antibody Test is a high performance, all-in-one, NP/SP COVID-19 antibody test with serological differentiation.
  • Pictor is pleased to partner with Mobility Health to offer such a unique and important test, said Howard Moore, CEO of Pictor.
  • Mobility Health is a member of the Mason, Ohio living lab initiative to scale biohealth start-up companies.. More information can be found at www.mobilityhealthlab.com .

35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer's oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries

Retrieved on: 
Thursday, March 17, 2022
LinkedIn, Ritonavir, World Health Organization, Public sector, Private sector, Public health emergency, Medicines Patent Pool, MPP, Government, World, SDC, Unitaid, Korea, Public Health Emergency of International Concern, Industry, Twitter, COVID-19, United Nations, Agency, HIV, Development, Tuberculosis, YouTube, Patient, Partnership, Pharmaceutical industry, Pfizer

The non-exclusive sublicences allow generic manufacturers to produce the raw ingredients for nirmatrelvir and/or the finished drug itself co-packaged with ritonavir.

Key Points: 
  • The non-exclusive sublicences allow generic manufacturers to produce the raw ingredients for nirmatrelvir and/or the finished drug itself co-packaged with ritonavir.
  • Six companies will focus on producing the drug substance, nine companies will produce the drug product and the remainder will do both.
  • The companies span 12 countries: Bangladesh, Brazil, China, Dominican Republic, Jordan, India, Israel, Mexico, Pakistan, Serbia, Republic of Korea, and Vietnam.
  • "Furthermore, 15 companies are signing their first licence with MPP, and we warmly welcome our new generic manufacturing partners."

35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer's oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries

Retrieved on: 
Thursday, March 17, 2022
LinkedIn, Ritonavir, World Health Organization, Public sector, Private sector, Public health emergency, Medicines Patent Pool, MPP, Government, World, SDC, Unitaid, Korea, Public Health Emergency of International Concern, Industry, Twitter, COVID-19, United Nations, Agency, HIV, Development, Tuberculosis, YouTube, Patient, Partnership, Pharmaceutical industry, Pfizer

The non-exclusive sublicences allow generic manufacturers to produce the raw ingredients for nirmatrelvir and/or the finished drug itself co-packaged with ritonavir.

Key Points: 
  • The non-exclusive sublicences allow generic manufacturers to produce the raw ingredients for nirmatrelvir and/or the finished drug itself co-packaged with ritonavir.
  • Six companies will focus on producing the drug substance, nine companies will produce the drug product and the remainder will do both.
  • The companies span 12 countries: Bangladesh, Brazil, China, Dominican Republic, Jordan, India, Israel, Mexico, Pakistan, Serbia, Republic of Korea, and Vietnam.
  • "Furthermore, 15 companies are signing their first licence with MPP, and we warmly welcome our new generic manufacturing partners."

Best’s Market Segment Report: Health Insurers Successfully Navigate Pandemic, Rapid Growth of Government Programs

Retrieved on: 
Tuesday, March 8, 2022
Insurance, Professional Services, Medicaid, COVID, Public health, Industry, Public health emergency, Income, Disease, Federation, News, Medicare, Vaccination, Data, AM Best, Forest Law Enforcement and Governance Program, COVID-19, Public Health Emergency of International Concern, Insurance, ALL, Pharmaceutical industry, Health insurance

The annual Review & Preview Bests Market Segment Report, titled, Health Insurers Successfully Navigate Pandemic and Rapid Growth of Government Programs, states that the favorable third-quarter earnings come on the heels of very strong years in 2019-2020, with net income of $34.3 billion and $41.1 billion, respectively.

Key Points: 
  • The annual Review & Preview Bests Market Segment Report, titled, Health Insurers Successfully Navigate Pandemic and Rapid Growth of Government Programs, states that the favorable third-quarter earnings come on the heels of very strong years in 2019-2020, with net income of $34.3 billion and $41.1 billion, respectively.
  • Industry premiums through the first three quarters of 2021 showed material year-over-year growth of 7.1%, to $798.6 billion, driven by enrollment increases in government programs.
  • The pandemic will continue to have an impact on health insurers in 2022, with a number of unknowns: how many more variants will occur, how long until COVID-19 becomes endemic and when the federal government will end the Public Health Emergency period.
  • Health insurers that are larger and more diversified have for the most part been able to manage any increases in claims, said Sally Rosen, senior director, AM Best.

In Shadow of Omicron, Leaders Agree to Start Pandemic Treaty Negotiation

Retrieved on: 
Wednesday, December 1, 2021
Public Policy, Government, Infectious Diseases, Health, Other Policy Issues, World Health Organization, Pandemic, World, Virus, Public health emergency, Vaccine, COVID-19, Air travel, World Health Assembly, Public Health Emergency of International Concern, Panel, Omicron, Gaps, Policy, Research, Public health, Disease, Negotiation, PPE, Animal, Pharmaceutical industry

We wholeheartedly commend the Member States of the World Health Organisation in their decision to go forward in negotiating a legally binding instrument.

Key Points: 
  • We wholeheartedly commend the Member States of the World Health Organisation in their decision to go forward in negotiating a legally binding instrument.
  • Member States recognized that we must all work together, collaboratively and in coordination.
  • We hope the negotiation will move with all speed to develop a robust and binding instrument.
  • Support accountability by accepting independent monitoring, as well as quick, transparent and independent verification of data, preparedness capabilities, and the adequacy of outbreak and pandemic response.

Joint statement to Leaders from Canada's Minister of Innovation, Science and Industry and the United States' Director of the White House Office of Science and Technology Policy

Retrieved on: 
Friday, November 19, 2021
COP26, Genomics, Technology, Industry, AI, Innovation, Science and Economic Development Canada, Economic development, Pandemic, Partnership, ST, Health, Public health emergency, Memorandum, Engineering, Natural Sciences and Engineering Research Council, NSERC, Quantum, Indigenous peoples, Solution, Therapy, Vaccine, Natural science, Public Health Emergency of International Concern, Goal, G20, NSF, Society, National Science Foundation, G7, Research, Artificial intelligence, Knowledge, Social media, Biomedical Research, Collaboration, OECD, Intelligence, Medical device, Pharmaceutical industry, Airline, Creative industries, Renewable energy, Risk management

Canada-U.S. ST&I relations are strong and diversified, with extensive collaborations between academic researchers, governments and industry.

Key Points: 
  • Canada-U.S. ST&I relations are strong and diversified, with extensive collaborations between academic researchers, governments and industry.
  • We look forward to seeing the positive results this is expected to bring to key areas of science and technology.
  • International science, technology, and innovation will continue to play an essential role in driving solutions to global economic, social, and environmental problems.
  • We intend to meet regularly on these and other topics of importance to the bilateral Canada-U.S. ST&I relationship.

Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, October 21, 2021
Safety, Death, Research, DRC, Assistant, Vaccine Research Center, Ecosystem, Filoviridae, Vaccine, Disease, Sabin, Marburg virus disease, Military personnel, Sabin Vaccine Institute, Viral hemorrhagic fever, Public Health Emergency of International Concern, Human, BARDA, Twitter, Partnership, Virus, Ebola River, Ebola, Primate, World Health Organization, Public health emergency, World, Ministry of Health (Saudi Arabia), Policy, Office of the Assistant Secretary for Preparedness and Response, Office of Inspector General, U.S. Department of Health and Human Services, Ministry, Biomedical Advanced Research and Development Authority, Polio, Infection, Public health, COVID-19, WHO, Solution, Development, GSK, GLOBE, Animal, Pharmaceutical industry

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.

Key Points: 
  • In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.
  • The two candidate vaccines, based on GSKs proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
  • Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses.
  • Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan.

AHF: UN Member States Must Nominate New WHO Chief

Retrieved on: 
Tuesday, September 7, 2021
Science, Public Policy, Government, Other Science, Public Policy, General Health, Health, Other Policy Issues, Infectious Diseases

As the process to submit names for a new WHO chief nears its end, AHF urges United Nations Member States to promptly nominate qualified candidates and appoint a new WHO Director-General at the end of the electoral proceedings in May 2022.

Key Points: 
  • As the process to submit names for a new WHO chief nears its end, AHF urges United Nations Member States to promptly nominate qualified candidates and appoint a new WHO Director-General at the end of the electoral proceedings in May 2022.
  • UN Member States must nominate and appoint a new Director-General.
  • UN Member States have until mid-September 2021 to submit candidates for the Director-General position.
  • If there is more than one candidate, a forum will convene in March 2022, before the final vote by Member States at the 75th World Health Assembly in May.

North America Collaborative Robots Market Report 2021: COVID-19 has had a Mixed Impact in Q1 2020 - Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Technology, Hardware, Articles, Contemporary history, Economy, COVID-19 pandemic, Occupational safety and health, Pandemics, Public Health Emergency of International Concern, Recession

The "North America Collaborative Robots Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Collaborative Robots Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 outbreak and the lockdown restriction imposed in North America have affected capital investments and industrial activities across the region.
  • Following the global economic recession led by COVID-19, the collaborative robot market in North America also has witnessed a mixed impact in Q1 2020.
  • The probability of new players entering the market is moderately high during the forecast period, further intensifying the market competition.

China Pharmaceutical Market and Healthcare Industry Forecast and Analysis Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Pharmaceutical, Health sciences, Health, Contemporary history, COVID-19 pandemic, Occupational safety and health, Pandemics, Public Health Emergency of International Concern, Healthcare industry, Pharmaceutical industry

The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has had quite an impact on the Chinese pharmaceutical and healthcare industry, through industry analysts expect a speedy recovery back to normal levels of demand.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • A SWOT analysis of the Chinese pharmaceutical and healthcare industry.